Direct Oral Anticoagulants (DOACs), Warfarin, Allopurinol, or Propylthiouracil Use in Patients with Cutaneous Small-Vessel Vasculitis: A Descriptive Analysis

    Basic Details
    Date Posted
    Wednesday, February 3, 2021
    Status
    Complete
    Medical Product
    allopurinol
    direct oral anticoagulant (DOAC)
    propylthiouracil
    warfarin
    Health Outcome(s)
    cutaneous small-vessel vasculitis
    Description

    The purpose of this request was to calculate the number of treated patients and time to treatment among patients diagnosed with cutaneous small-vessel vasculitis (CSVV) in the IBM® MarketScan® Research Databases who had prior use of four medical products: direct oral anticoagulants (DOACs), warfarin, allopurinol, and propylthiouracil. The post-CSVV treatments of interest were predinose/prednisolone alone as well as prednisone/prednisolone combined with an autoimmune medication. The results of this query were used for subsequent Patient Episode Retrieval (PEPR) sampling to further evaluate treatment patterns among patients with CSVV.

    The study period included data from October 19, 2010 to December 31, 2018. We executed this request on IBM® MarketScan® Research Databases on December 19, 2019.

    Additional Details
    FDA Center
    CDER
    Time Period
    October 19, 2010 - December 31, 2018
    Study Type
    Modular Program
    Assessment Type
    Exploratory Analyses
    Population / Cohort
    Individuals 21 years of age and older
    Data Sources
    IBM® MarketScan® Research Databases